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Until today the role of oxygen in the development of the fetus remains controversially discussed. It is still believed that lack of
oxygen in utero might be responsible for some of the known congenital cardiovascular malformations. Over the last two decades
detailed research has given us new insights and a better understanding of embryogenesis and fetal growth. But most importantly
it has repeatedly demonstrated that oxygen only plays a minor role in the early intrauterine development. After organogenesis
has taken place hypoxia becomes more important during the second and third trimester of pregnancy when fetal growth occurs.
This review will briefly adress causes and mechanisms leading to intrauterine hypoxia and their impact on the fetal cardiovascular
system.
1. Introduction
Embryogenesis, fetal growth, and survival of the perinatal
period all depend on optimal maternal health and normal
placental development. Maternal exposure to a persistently
hypoxic environment may lead to critical injury to vital
organs. Failure of the normal placental function may have
profound acute and chronic effects on the developing fetus
and lead to intrauterine growth restriction (IUGR), asphyxia,
multiorgan failure, premature delivery, and perinatal demise.
In the United States, IUGR and prematurity complicate
about 12% of the deliveries and represent the leading cause of
perinatal mortality and morbidity to this day, accounting for
up to 75% of perinatal deaths. Long-term disabilities such as
cerebral palsy, hearing loss, retinopathies, and chronic lung
disease are associated with a substantial emotional burden
for affected families and health care costs to the society [1].
In this paper, we will briefly adress relevant aspects of the
normal fetomaternal physiology and then focus our attention
on the causes of chronic intrauterine hypoxia and how
this affects the development and performance of the fetal
heart.
2. Normal Pregnancy
The process of placentation is initiated once the blastocyst
makes contact with the epithelium of the uterus. An initial
trophoblastic shell is penetrated by columns of proliferating
extravillous cytotrophoblast that form the anchoring vili and
provide specialized invasive cells that transform the decidual
and proximal portions of the decidual spiral arteries [2].
During the initial phase of implantation and uterine wall
invasion, the main role of extravillous trophoblast is to
form plugs that occlude capillaries in the endometrial gland
stroma; this prevents maternal hemorrhage form disrupting
the conceptus and maternal blood from entering the lacunar
spaces of the trophoblastic shell. Embryogenesis thus takes
place in a hypoxic environment for the first 10 weeks of
pregnancy because oxygen tension within the placenta is
much lower than in the surrounding endometrial glands [3–
6]. The “plugging” mechanism protects the growing embryo
and the primitive placental villi against oxidative damage;
antioxidant enzymes such as mitochondrial superoxide dis-
mutase are not expressed by the syncytiotrophoblast before 8
to 9 weeks of gestation [7, 8]. In the period of 11–13 weeks,s
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the trophoblastic plugs are breached by maternal blood that
now enters the intervillous space. Uteroplacental blood flow
increases exponentially from less than 50mL/min in the
nonpregnant state to approximately 350mL/min by fullterm.
The demands of this large rise in uteroplacental blood flow
(to 20% of the total maternal cardiac output), require large
adaptations in maternal physiology [9].
The maternal cardiac output increases by 20% to 25%
during the first trimester. It reaches its peak at the beginning
of the third trimester when it exceeds the prepregnancy
output by 30% to 40%. This is primarily achieved by an
increase in the circulating blood volume resulting in a rise
in stroke volume of about 30%, by an increase in the resting
heart rate of 10 to 20 beats/min and by lowering the systemic
arterial blood pressure secondary to the effects of gestational
hormones, circulating prostaglandins, the excessive release
of human placental growth factors, and the low-resistance
uteroplacental unit [10–13]. The increase of total blood
volume is related to plasma expansion by 30 to 40mL/kg
body weight rather than an increase in total red blood cells
and accounts for the relative anemia of pregnant women.
The increased cardiac output together with the low blood
viscosity lead to a rightward shift of the hemoglobin-oxygen
dissociation curve [13–16]. The maternal gas exchange
adapts in parallel with the hemodynamic changes. The
increase in fetal-maternal oxygen demand is achieved by
mild hyperventilation and anatomical changes that allow the
mother to maintain her natural lung capacity despite the
increase of the intra-abdominal volume.
Increased production of endothelial nitric oxide and
other vasodilators in conjunction with attenuated adrenergic
vascoconstriction is thought to be responsible for maintain-
ing uterine artery flow [17–19]. By midgestation, the human
uterine artery has doubled its diameter and the increased
flow is accommodated by hyperplasia of all cell layers [20–
22].
2.1. Embryonic Heart Development. The embryonic heart
develops early post conception from its origins in the heart
field to a completely looped 4-chamber organ by 8 weeks of
gestation [23–28]. During this period the oxygen saturation
never exceeds 20%, protecting the embryo from oxidative
damage [6–8]. By the time the extravillous spaces of the
trophoblast are starting to be filled with maternal blood,
the newly-formed fetal heart is ready to meet the increasing
oxygen and nutritional demands of the growing fetus [7,
9]. The fetal oxygen saturation gradually increases during
the 2nd trimester to about 60%. To maintain an adequate
circulation, the fetal heart adjusts continuously to the rise
in circulatory blood volume and pressure load. The right
and left ventricles work in parallel, adjusting their outputs
via several prenatal shunts that will close in the immediate
postnatal period.
3. Intrauterine Hypoxia
Intrauterine hypoxia is associated with a variety of maternal,
placental, and fetal conditions which may manifest differ-
ently and have different outcomes. Kingdom and Kaufmann
[29] suggested to classify hypoxic pregnancy conditions
into 3 subtypes: (1) preplacental hypoxia, where both the
mother and her fetus will be hypoxic (i.e., high-altitude,
cyanotic maternal heart disease; etc.); (2) uteroplacental
hypoxia, where the maternal oxygenation is normal but the
utero-placental circulation is impaired (i.e., preeclampsia,
placentar insufficiency, etc.); (3) postplacental hypoxia, where
only the fetus is hypoxic. We will focus on the first 2
subtypes as the post-placental hypoxia is mainly related to
fetal diseases rather than to the direct impact of hypoxia onto
the fetus.
3.1. Pre-Placental Hypoxia. Main causes of pre-placental
hypoxia are a hypoxic environment (high-altitude) and pre-
existing maternal cardiovascular disease such as cyanotic
heart disease, heart failure, or pulmonary hypertension.
Maternal anemia, infections, and chronic inflammation may
further limit thematernal oxygen uptake and oxygen delivery
to the fetus, thereby increasing the risk for adverse pregnancy
outcomes.
Chronic hypoxia associated with placental insufficiency
plays a key role in the etiology of intrauterine growth restric-
tion (IUGR). High-altitude exposure mimics this condition
and its adverse effects on birth weight exceed those of most
other risk factors for IUGR, such as maternal low weight
gain, smoking, primiparity, or pre-eclampsia [30]. A 1000
meter gain in altitude results in a natural average decline of
the birth weight of 100 grams [30–32]. Intrauterine growth
of the chronically hypoxemic fetus generally begins to slow
down between gestational week 25 to 31, a time when fetal
growth normally increases exponentially [33]. Interestingly,
high-altitude exposure appears also to be associated with an
increased risk of pre-eclampsia that may further contribute
to low birth weights in high-altitude populations [34].
Nevertheless, in most cases arterial hypertension during
pregnancy at high-altitude is probably related to chronic
hypoxia rather than to classic pre-eclampsia [34–36]. In
line with this concept, pregnant women at high-altitude
lack the physiological blood pressure fall at the beginning
of the second trimester [36, 37]. A possible explanation
is that chronic hypoxia diminishes the vasodilatory effect
of nitric oxide while the sympathetic nervous system (∝1-
/∝2-adrenergic receptor) is activated [10, 17, 18, 38–40].
In addition, potent vasoconstrictors like endothelin-1 and
the hypoxia-inducible factor (HIF) are stimulated early in
pregnancy by excessive generation of reactive-oxygen species
(ROS) [41]. Altitude may also influence cardiac performance
and the circulating blood volume. Cardiac output is lower
presumably due to a lower heart rate and smaller stroke
volumes related to a decreased blood volume of women
living permanently at high-altitude [42, 43]. Finally, uterine
arteries are typically smaller in diameter and less well
perfused during pregnancy at high-altitude [44]. A direct
association between uterine arterial flow and birth weight
is supported by studies conducted in women from different
origins [45, 46].
Women with congenital heart disease are at increased
risk of developing pregnancy complications [47]. The prob-
ability of maternal complications has been classified as low,
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intermediate, or high, with estimates of 5%, 25%, and 75%,
respectively, of experiencing cardiac events such as arrhyth-
mias, pulmonary edema, stroke, or cardiac death during
pregnancy [48]. The highest risk is observed in mothers
with severe left-sided obstructive lesions (i.e., aortic stenosis,
coarctation), pulmonary hypertension, Marfan syndrome
with aortic root dilatation, as well as with symptoms of mod-
erate or severe heart failure (NYHA functional class III and
IV). Increasing maternal hypotension is the most important
factor associated with intrauterine growth restriction (20%
to 25%) and prematurity (20% to 25%) [49]. Interestingly,
unrepaired or palliated cyanotic congenital heart disease does
not belong to the high-risk group for an adverse maternal
outcome but is associated with an increased risk of fetal
loss. The live-birth rate is reportedly only 40% to 45% if
the mother has cyanotic heart disease. This rate decreases
to 10%–15% if the maternal oxygen saturation drops below
85%. In addition, extreme prematurity affects 35% to 40%
of these pregnancies [50]. Fetal or neonatal death, brain
hemorrhage secondary to maternal anticoagulation or to
extreme prematurity, as well as IUGR are common findings
in offspring of pregnant women with congenital or acquired
heart disease [47, 48, 51].
Chronic pulmonary disease may have similar maternal-
fetal consequences as chronic exposure to hypoxia [52].
Poorly controlled asthma is associated with pre-eclampsia,
uterine hemorrhage, preterm delivery, and low birth weight
[53, 54]. Among chronic lung diseases, cystic fibrosis (CF)
and tuberculosis are the most common conditions: 5% of
the world population is carrying the CF gene and 30% of
humans have been infected withmycobacterium tuberculosis
[55, 56]. Pregnancy in cystic fibrosis patients seems to have
a positive effect on maternal long-term survival, despite the
increased maternal risk for infections and insulin resistance
and the increased fetal risk of prematurity and IUGR [57–
61].
Acute respiratory infections during pregnancy are com-
mon. 1% of women experience symptoms of bronchitis
or pneumonia during the course of pregnancy. Current
antibiotic regimens have decreased maternal mortality from
bacterial pneumonia dramatically, with the exception of
cystic fibrosis. Nowadays viral pneumonias are responsible
for the major part of maternal deaths during pregnancy
[52]. The major risk for the fetus lies in maternal respiratory
failure due to ARDS [52, 62, 63]. Fetal complications include
stillbirth, spontaneous preterm labor, and a need for early
delivery by Cesarean section to improve the effectiveness of
maternal ventilation for respiratory failure.
Maternal hematological disorders may directly affect oxy-
gen transfer. Iron deficiency anemia (IDA) is common in
pregnancy and often related to malnutrition or micronu-
trient diets [64–67]. IDA is associated with increased risk
for IUGR and prematurity [65, 68–70]. In contrast to IDA,
the oxygen carrier capacity is altered in hemoglobinopathies.
Sickle cell disease is particularly common in Africans and
Afro-Americans [71, 72]. It may be present in combination
with hemoglobin C or β-thalassemia (Hb S/C or Hb S/β).
The most severe form (homozygous HbS) is called sickle cell
anemia but any Hb S combination (Hb S/C or Hb S/β) can
potentially cause vaso-occlusive crisis and hemolysis [73].
This problem is caused by the abnormal rigid sickle shape of
the red blood cells with decreasing oxygen tension. Patients
with sickle cell disease are at higher risk for maternal (i.e.,
preterm labor, preterm rupture of membranes, and post-
partum infections) and fetal complications (i.e., abortion,
prematurity, IUGR, low birth weight, and stillbirth) [74].
Close fetal monitoring during pregnancy and prophylactic
exchange transfusion seem to be often effective in abolishing
life-threatening intrauterine hypoxic events [75].
Thalassemia is an autosomal recessive blood disease
which is particularly prevalent in Asians (α-form) and
among Mediterranean people (β-form). The genetic defect
results in a reduced synthesis rate of α- or β-globin chains
that make up hemoglobin [73, 76]. Homozygous individ-
uals present with severe anemia (Cooley’s anemia) and
extramedullary erythropoiesis. Alpha-Thalassemia major
(Hb Bart’s) is associated with hydrops fetalis, intrauterine
death, and pre-eclampsia [71]. β-Thalassemia is a result of
a mutation in the β-globin gene causing deficient or absent β
chain production with absence of hemoglobin. The clinical
picture of β-thalassemia varies in severity in function of
the expression of Hb A. Pregnancy in thalassemia carriers
is usually uncomplicated. Successful pregnancies in women
with α- and β-thalassemiamajor have been reported but were
associated with a higher incidence of IUGR, low birth weight,
and prematurity [77–79].
3.2. Utero-Placental Hypoxia. Utero-placental hypoxia is
related to abnormal placentation early in gestation and
to placental vascular disease later in pregnancy. Abnormal
placental implantation is a common finding in pregnancies
complicated by IUGR, by gestational hypertension, and by
pre-eclampsia. There exists an increased risk for both the
mother and the fetus to develop cardiovascular disease later
in life [68, 80–91].
Pre-Eclampsia. It is a complex multisystem disorder obser-
ved in human pregnancy. Maternal clinical manifestations
range from mild hypertension and proteinuria to fully
established HELLP syndrome (Hemolysis, Elevated Liver
enzymes, Low Platelet count) or eclampsia with severe
hypertension, proteinuria, and multiorgan involvement
(pulmonary edema, CNS symptoms, oliguria, thrombocy-
topenia, and liver failure) [92–95].
Causes for its origin are largely unknown but may be the
result of a systemic inflammatory response perhaps related
to an immature maternal immune response [35]. Key abnor-
malities of pre-eclampsia include a rise in systemic vascular
resistance, endothelial dysfunction, and activation of the
coagulation system with enhanced platelet aggregation [92].
Endothelial dysfunction is responsible for the impaired gen-
eration and activity of vasodilators such as prostacyclin and
NO and could explain surface-mediated platelet activation
and fibrin formation in the uteroplacental circulation [96].
Depending on the severity of the pre-eclampsia, the
condition may lead to intrauterine hypoxia and/or oxida-
tive stress in the fetus. Pre-eclampsia is associated with
IUGR and prematurity [89]. Fetal morbidity and mortality
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increase significantly when pre-eclampsia develops prior
to 33 gestational weeks [97–100]. Pre-eclamptic mothers
and their offspring are at an increased risk for premature
cardiovascular disease later in life [101].
3.3. Post-Placental Hypoxia. In post-placental hypoxia, only
the fetus becomes hypoxic which is either related to dimin-
ished uterine artery flow (i.e., mechanical compression,
rupture, and thrombotic occlusion), progressive fetal cardiac
failure (i.e., complete congenital heart block, complex con-
genital heart malformations), or due to important genetic
anomalies. As mentioned earlier, we will not further explore
the post-placental hypoxia as it is mainly related to fetal
diseases rather than to the impact of hypoxia onto the fetus.
3.4. Effects of Hypoxia on the Fetus. A main consequence
of chronic hypoxia is the failure of the fetus to achieve its
genetically determined growth potential. About 10% of all
babies grow poorly inutero and are born small for gestational
age. IUGR is associated with distress and asphyxia and a
6- to 10-fold increased perinatal mortality [102]. Frequent
hypoxia-mediated complications include meconium aspi-
ration, metabolic and hematologic disturbances, cognitive
dysfunction, and cerebral palsy. Acute and chronic hypoxia
is also associated with a variety of morphological and func-
tional fetal cardiac changes that aim either to compensate for
the reduced oxygenation of vital organs or are the result of
hypoxia-mediated fetal tissue damage [103–105].
3.4.1. Hemodynamic Consequences. At an initial stage, the
human fetus may be able to adapt to hypoxia by increasing
the blood supply to the brain, myocardium, and upper body
and decreasing the perfusion of the kidneys, gastrointestinal
tract, and lower extremities. This redistribution of blood
allows preferential delivery of nutrients and oxygen to the
most vital organs. Cerebral vasodilatation to spare the brain
from hypoxic damage leads to a decrease in left ventricular
afterload while systemic arterial vasoconstriction of lower
body vessels increases right ventricular afterload [106, 107].
In line with this concept, echocardiographic studies in the
hypoxic fetus demonstrate an increased middle cerebral
artery blood flow and a shift of the cardiac output in favor of
the left ventricle [108, 109]. With further deterioration of the
fetal oxygenation, this protective mechanism is overwhelmed
by the decline in cardiac output and the emergence of fetal
distress. The final stage is characterized by a decline in
systolic and diastolic fetal cardiac function, secondary to
myocardial ischemia [110]. Moreover, raised atrial contrac-
tion results in the transmission of atrial pressure waves into
the venous duct and umbilical vein, causing end-diastolic
umbilical vein, pulsation [111]. At this stage, reduced or
reversed end-diastolic flow velocity may also be found in
pulmonary veins and coronary blood flow may become
visible with increased systolo-diastolic flow velocities (“heart
sparing”). If not delivered, intrauterine death occurs usually
within a few days [112].
In line with these findings in the hypoxic human fetus,
in the hypoxic fetal sheep the cardiac output is reduced
whereas the hemoglobin level is increased tomaintain a near-
normal oxygen delivery to the fetal myocardium [113, 114].
Moreover, in this hypoxic animal model, the coronary blood
flow of the fetus is increased although there is no change
in capillary/muscle fiber ratio, capillary volume density, or
capillary diameter, and myocardial contractility is reduced
[113–117].
While chronic hypoxia has detrimental consequences
for the fetal heart, chronic anemia appears to have less
detrimental effects because the higher oxygen affinity of
fetal hemoglobin allows to compensate for this problem. In
maternal anemia-related hypoxia, the fetus is able to increase
the cardiac output and to increase the transplacental oxygen
transfer by actively interfering with the iron metabolism of
the mother.
Surviving babies seem to be particularly susceptible to
the development of arterial hypertension and cardiovascular
disease later in life. An association between low birth
weight and early onset of essential arterial hypertension
has first been postulated by Barker in the “fetal origins
of adult disease hypothesis” [118]. Barker’s theory states
that physiologic adaptations that enable the fetus to survive
a period of intrauterine deprivation result in permanent
reprogramming of the development of key organs that may
have pathological consequences in postnatal life. In older
children and adults, a low birth weight has been linked
with increased arterial stiffness, systolic blood pressure,
premature coronary heart disease, stroke and diabetes [68,
83–85, 87, 119–129], and ischemia/reperfusion injury (139–
45). Despite the strong epidemiologic evidence that supports
the concept of “fetal programming”, we still do not know its
underlying mechanisms.
3.4.2. Teratogenicity. Recently it has also been suggested that
hypoxia early in gestation may be teratogenic to the human
embryo. As such, maternal asthma exacerbation during the
first trimester of pregnancy reportedly increased the risk
for congenital malformations including the risk of cardio-
vascular malformations [130]. As described above, maternal
blood enters the intervillous space of the human placenta
only after 10 to 12 gestational weeks and until this moment
the placental metabolism is anaerobic [3, 7]. Yet, the human
heart forms early in the period of anaerobic metabolism
between day 15 and day 60 postconception. Interestingly,
if animal embryos are exposed to chronic hypoxia, cardiac
malformations seem not occur more frequently.
3.4.3. Cellular Effects of Hypoxia. In rats, early fetal hypoxia
triggers cardiac remodeling associated with enhanced apop-
tosis and a significant increase in binucleatedmyocytes [131].
At the age of 4 months, fetal hypoxia was associated with
increased heart/body weight ratio presumably due to hyper-
trophy of myocardium in presence of slowed fetal growth,
increased β-/α-myosin heavy chain ratio, increased collagen
I and III expression, and lower matrix metalloproteinase-2
activity. The consequences of these changes are higher end-
diastolic pressure related to less compliant left ventricle and
a reduced capability to recover from ischemia.
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Apoptosis is a controlled active physiologic process
that removes unwanted or defective cells by intrinsic pro-
grammed cellsuicide [105]. In rat hearts exposed to oxidative
stress, it could be shown that many genes that affect cell
communication, survival and signaling were downregulated
[105, 131]. This downregulation is believed to be partly
responsible for the long-term consequences of intrauterine
hypoxia and leaves a persistent cardiovascular “imprint” that
leads to cardiovascular disease in later life. The transcription
of the heat shock gen Hsp70 might be an example of this
observed cardiac programming phenomenon. Hsp70 is a
protein that protects against myocardial ischemia and stress
(hyperthermia) and inhibits apoptosis by preventing the
formation of caspase-9 [132–134]. In chronic intrauterine
hypoxia conditions, the expression of Hsp70 is down-
regulated [135]. This effect persists into adulthood and may
explain why some adult hearts are more vulnerable against
ischemia/reperfusion injury [132–138]. The expression of
endothelial nitric oxide is also important for the long-
term cardioprotection of the cardiomyocytes. eNOS levels
are also decreased in rat hearts who were exposed to
intrauterine hypoxia [139]. Similar changes were observed
in the regulation of the β-adrenoreceptors (βARs) and
the coupling G proteins. β2AR and Gsα are upregulated
in adult rat hearts that were inutero exposed to chronic
hypoxia. This upregulation preserves cardiac contractility in
hypoxia, but the regulatory mechanism appears to be lost in
adulthood presumably due to wrong prenatal programming
[140, 141].
4. Conclusion
Hypoxia does not play a major role in the early development
of structural cardiac malformations probably because early
embryogenesis already takes place under anaerobic condi-
tions. Only during the second and third trimester, oxygen
becomes more important for the normal fetal organo-
genesis and growth. If at that stage exposed to hypoxia,
the fetus has a number of protective options. Immediate
protection against oxidative stress is established by up-
regulation of genes. Stimulation of nitric oxide synthesis
enhances cell signaling for defense mechanisms, platelet
inhibition, and regulation of apoptosis. β2AR and Gsα will
be up-regulated to maintain a sufficient cardiac output.
With persistent hypoxia, premature exit of cell cycle is
initiated, together with enhanced apoptosis resulting in
fewer, but hypertrophied cardiomyocytes. This process aims
for better energy efficiency during hypoxic conditions but
also results in less compliant ventricles. Altered regulatory
gene expression in response to in-utero hypoxia appears
to extend into adulthood and mimics the changes that
are found in adults with chronic heart failure. Hypoxia
slows fetal growth, and growth restriction is now consid-
ered a risk factor of premature arterial hypertension and
cardiovascular disease, probably secondary to endothelial
dysfunction. Further investigations are needed to explore
preventative strategies such as the early use of antioxidants
and selective vasodilators to limit the effects of intrauterine
hypoxia.
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